Herantis Pharma Oyj
- Address
- Bertel Jungin Aukio 1
Sponsor Overview
Specializations
Parkinson’s disease
Herantis Pharma Oyj is involved in clinical research focused on Parkinson’s disease, with interest in therapies aimed at addressing the neurological and motor symptoms associated with this neurodegenerative disorder. The sponsor’s trial activity includes work in both healthy volunteers and people living with Parkinson’s disease, reflecting a clinical focus on central nervous system treatment development.
- Neurodegenerative disease research
- Movement disorder therapeutics
- Central nervous system drug development
Its research landscape is centred on therapies intended to support neurological function and address unmet needs in Parkinsonian care.
Safety and tolerability in neurological therapy
The sponsor’s clinical activity includes evaluation of safety and tolerability in the context of neurological treatment, with attention to how investigational approaches are handled in both healthy participants and patients with Parkinson’s disease. This area reflects an emphasis on clinical acceptability and patient suitability in neurology.
- Safety assessment
- Tolerability evaluation
- Neurology-focused clinical development
The therapeutic interest lies in advancing candidate treatments for Parkinson’s disease through careful clinical assessment of their use in human subjects.
Pharmacokinetics and systemic exposure
Herantis Pharma Oyj also shows interest in pharmacokinetic profiling within neuroscience-oriented drug development, supporting understanding of how investigational therapies are processed in the body. This includes clinical attention to systemic exposure and treatment behaviour relevant to subcutaneous administration.
- Pharmacokinetic analysis
- Subcutaneous delivery
- Drug disposition
These interests align with efforts to characterise candidate medicines intended for Parkinson’s disease treatment.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase Ib Evaluation of Safety, Tolerability, and Pharmacokinetics of Subcutaneous HER-096 in Healthy Volunteers and Parkinson's Disease Patients |  Finland | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 2 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
2 centres- Address
- Itainen Pitkakatu 4b, 20520 Turku
- Address
- Energiakatu 4, 00180 Helsinki
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Herantis Pharma Oyj.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.